Glenmark Gets Final USFDA Nod for Clobetasol Propionate Cream | CORPORATE ETHOS

Glenmark Gets Final USFDA Nod for Clobetasol Propionate Cream

By: | May 11, 2018
Glenmark

May 11: Glenmark Pharmaceuticals Inc., USA, the US division of Mumbai-based drug manufacturer Glenmark Pharmaceuticals Ltd, has been granted final approval by the United States Food & Drug Administration (USFDA) for its Clobetasol Propionate Cream USP, 0.05%, the generic version of Temovate Cream, 0.05%, of Fougera Pharmaceuticals, Inc.

According to IQVIATM sales data for the 12 month period ending March 2018, the Temovate Cream, 0.05% market achieved annual sales of approximately $118.0 million.

Glenmark’s current portfolio consists of 134 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA.

Glenmark shares were trading in red at Rs 512.35, down 0.72% from the previous closing of Rs 516.05, on BSE at 10.10 am today.